What is BBB Technologies?
BBB Technologies, operating within the advanced diagnostics sector, is focused on developing innovative in vitro diagnostic (IVD) solutions. Their flagship technology, the MARK-B quantitative immunoassay biosensor, is engineered for the precise diagnosis and management of critical health conditions including infectious diseases, cancer, and cardiovascular ailments. The system is designed for high accuracy and full automation, delivering lab-quality results in minutes without the need for pre-processing. Leveraging a patented magnetic electrochemical sandwich immunoassay method, BBB Technologies offers a broad spectrum of tests targeting tumors, cardiovascular markers, infectious agents, and more, positioning itself as a key provider for healthcare entities seeking efficient and exact diagnostic tools.
How much funding has BBB Technologies raised?
BBB Technologies has raised a total of $5M across 1 funding round:
Series A
$5M
Series A (2016): $5M with participation from POSCO Capital
Key Investors in BBB Technologies
POSCO Capital
POSCO Capital is a prominent South Korean investment firm, likely focusing on strategic technology and industrial advancements, as indicated by its affiliation with the global steel manufacturing giant POSCO.
What's next for BBB Technologies?
The recent major strategic investment in BBB Technologies signals a pivotal moment for the company, likely enabling accelerated product development, market expansion, and the scaling of its innovative IVD solutions. This infusion of capital is expected to bolster its research and development efforts, enhance manufacturing capabilities, and strengthen its commercialization strategy. The company's focus on automated, rapid diagnostics for complex diseases positions it to capitalize on the growing demand for point-of-care testing and advanced medical diagnostics, suggesting a trajectory towards broader adoption and significant market impact.
See full BBB Technologies company page
